Todd S Crocenzi
Overview
Explore the profile of Todd S Crocenzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
10624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
118(1):107-114.
PMID: 37598723
Purpose: NRG/Radiation Therapy Oncology Group 0848 is a 2-step randomized trial to evaluate the benefit of the addition of concurrent fluoropyrimidine and radiation therapy (RT) after adjuvant chemotherapy (second step)...
2.
Martin 2nd R, Simo K, Hansen P, Rocha F, Philips P, McMasters K, et al.
Ann Surg Oncol
. 2022 Jun;
29(9):5462-5473.
PMID: 35657463
Background: Unresectable intrahepatic cholangiocarcinoma (ICC) carries a poor prognosis, and currently there are moderately established chemotherapeutic [gemcitabine/cisplatin (Gem/Cis)] treatments to prolong survival. The purpose of this study was to assess...
3.
Handy J, Bremner R, Crocenzi T, Detterbeck F, Fernando H, Fidias P, et al.
Ann Thorac Surg
. 2018 Nov;
107(2):631-649.
PMID: 30476477
No abstract available.
4.
Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L, et al.
Science
. 2017 Jun;
357(6349):409-413.
PMID: 28596308
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were...
5.
El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C, et al.
Lancet
. 2017 Apr;
389(10088):2492-2502.
PMID: 28434648
Background: For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed...
6.
Martin 2nd R, Scoggins C, Schreeder M, Rilling W, Laing C, Tatum C, et al.
Cancer
. 2015 Jul;
121(20):3649-58.
PMID: 26149602
Background: Reports have demonstrated the superior activity of combining both irinotecan and oxaliplatin (FOLFOXIRI) therapy. An option for gaining similar benefits with less toxicity would be the administration of irinotecan...
7.
Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A, et al.
N Engl J Med
. 2015 Jun;
372(26):2509-20.
PMID: 26028255
Background: Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to...
8.
To Y, Sutcliffe K, Hoen H, Swaney R, Nicholls J, Crocenzi T
J Oncol Pharm Pract
. 2015 Mar;
22(2):256-60.
PMID: 25762052
Purpose: Oxaliplatin, a platinum-type alkylator, is not classified as a vesicant but can cause local reactions when infused by peripheral vein. Providence Cancer Center, like other institutions, deferred the venous...
9.
Payne R, Glenn L, Hoen H, Richards B, Smith 2nd J, Lufkin R, et al.
J Immunother Cancer
. 2014 May;
2:13.
PMID: 24855563
Background: High-dose interleukin-2 (IL-2) has been FDA-approved for over 20 years, but it is offered only at a small number of centers with expertise in its administration. We analyzed the...
10.
Dandamudi U, Ghebremichael M, Sosman J, Clark J, Mcdermott D, Atkins M, et al.
J Immunother
. 2013 Oct;
36(9):490-5.
PMID: 24145360
Overexpression of vascular endothelial growth factor in renal cell carcinoma (RCC) leads to angiogenesis, tumor progression, and inhibition of immune function. We conducted the first phase II study to estimate...